title: Severe hepatotoxicity associated with the dietary supplement LipoKinetix.
abstract: BACKGROUND
  LipoKinetix (Syntrax, Cape Girardeau, Missouri) is a dietary supplement marketed for weight loss.
  
  
  OBJECTIVE
  To describe a possible causal association between LipoKinetix and hepatotoxicity.
  
  
  METHODS
  Case series.
  
  
  METHODS
  Outpatient clinic, tertiary care hospital, and U.S. Food and Drug Administration databases.
  
  
  METHODS
  Routine medical and supportive care.
  
  
  METHODS
  Clinical and laboratory evaluation.
  
  
  RESULTS
  All patients developed acute hepatotoxicity within 3 months of starting LipoKinetix. At presentation, symptoms and results of laboratory tests were characteristic of acute hepatitis. All patients recovered spontaneously after LipoKinetix use was discontinued. Three of the seven patients, including one who developed fulminant hepatic failure complicated by cerebral edema, were taking LipoKinetix alone at the time of presentation. Of the four patients who were taking multiple supplements, two resumed taking supplements other than LipoKinetix without incident.
  
  
  CONCLUSIONS
  The use of LipoKinetix may be associated with hepatotoxicity. Despite extensive evaluations, no other cause for hepatotoxicity could be identified in the seven patients studied.
authors.affiliation: Cedars-Sinai Medical Center, Burns and Allen Research Institute, University of California, Los Angeles, School of Medicine, Los Angeles, California 90048, USA. joya.favreau@cshs.org
authors.forename: Joya T
authors.initials: JT
authors.lastname: Favreau
authors.forename: Mina L
authors.initials: ML
authors.lastname: Ryu
authors.forename: Glenn
authors.initials: G
authors.lastname: Braunstein
authors.forename: Greg
authors.initials: G
authors.lastname: Orshansky
authors.forename: Sean S
authors.initials: SS
authors.lastname: Park
authors.forename: Gary L
authors.initials: GL
authors.lastname: Coody
authors.forename: Lori A
authors.initials: LA
authors.lastname: Love
authors.forename: Tse-Ling
authors.initials: TL
authors.lastname: Fong
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D001572:Benzofurans; D001578:Benzopyrans / Q000009:adverse effects*; D002110:Caffeine / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D019587:Dietary Supplements / Q000009:adverse effects*; D004104:Diiodothyronines / Q000009:adverse effects*; D017277:Drug Approval; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D010665:Phenylpropanolamine / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration; D015016:Yohimbine / Q000009:adverse effects*
chemical_list: D001572:Benzofurans; D001578:Benzopyrans; D004104:Diiodothyronines; D004338:Drug Combinations; C453460:lipokinetix; D015016:Yohimbine; D010665:Phenylpropanolamine; D002110:Caffeine